中国乳腺癌新辅助治疗专家共识(2022年版)

2022-01-27 《中国乳腺癌新辅助治疗专家共识 中国癌症杂志

新辅助治疗已经成为乳腺癌综合治疗中非常重要的组成部分,2019年中国乳腺癌新辅助治疗专家组就新辅助治疗的目的、适应证、评估规范、手术治疗原则及新辅助系统治疗的策略进行了详细探讨和阐述,结合近两年新的循

中文标题:

中国乳腺癌新辅助治疗专家共识(2022年版)

发布日期:

2022-01-27

简要介绍:

新辅助治疗已经成为乳腺癌综合治疗中非常重要的组成部分,2019年中国乳腺癌新辅助治疗专家组就新辅助治疗的目的、适应证、评估规范、手术治疗原则及新辅助系统治疗的策略进行了详细探讨和阐述,结合近两年新的循证医学证据和学术理念,对新辅助治疗临床实施规范和治疗原则予以更新和说明。 

相关资料下载:
[AttachmentFileName(sort=1, fileName=中国乳腺癌新辅助治疗专家共识(2022年版).pdf)] GetToolGuiderByIdResponse(projectId=1, id=92c1f1c002350a74, title=中国乳腺癌新辅助治疗专家共识(2022年版), enTitle=, guiderFrom=中国癌症杂志, authorId=0, author=, summary=新辅助治疗已经成为乳腺癌综合治疗中非常重要的组成部分,2019年中国乳腺癌新辅助治疗专家组就新辅助治疗的目的、适应证、评估规范、手术治疗原则及新辅助系统治疗的策略进行了详细探讨和阐述,结合近两年新的循, cover=https://img.medsci.cn/2022210/1644504285188_5579292.png, journalId=0, articlesId=null, associationId=2388, associationName=《中国乳腺癌新辅助治疗专家共识, associationIntro=《中国乳腺癌新辅助治疗专家共识(2022年版)》专家组, copyright=0, guiderPublishedTime=Thu Jan 27 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p style="color: #333333;"><span id="ChDivSummary">新辅助治疗已经成为乳腺癌综合治疗中非常重要的组成部分,2019年中国乳腺癌新辅助治疗专家组就新辅助治疗的目的、适应证、评估规范、手术治疗原则及新辅助系统治疗的策略进行了详细探讨和阐述,结合近两年新的循证医学证据和学术理念,对新辅助治疗临床实施规范和治疗原则予以更新和说明。&nbsp;</span></p>, tagList=[TagDto(tagId=285, tagName=乳腺癌), TagDto(tagId=100038, tagName=乳腺癌新辅助治疗), TagDto(tagId=117297, tagName=妇瘤乳腺肿瘤)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=24, categoryName=胸心外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5364, appHits=286, showAppHits=0, pcHits=805, showPcHits=5078, likes=0, shares=76, comments=2, approvalStatus=1, publishedTime=Fri Feb 11 15:42:00 CST 2022, publishedTimeString=2022-01-27, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Thu Feb 10 22:46:04 CST 2022, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Fri Jan 05 23:30:15 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=中国乳腺癌新辅助治疗专家共识(2022年版).pdf)])
中国乳腺癌新辅助治疗专家共识(2022年版).pdf
下载请点击:
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1208543, encodeId=850212085434d, content=收获很大!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99956477261, createdName=ms2000001769569573, createdTime=Mon Apr 04 15:29:30 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200788, encodeId=26661200e8838, content=收获多多, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b415562646, createdName=ms9000001873897494, createdTime=Wed Mar 09 08:28:17 CST 2022, time=2022-03-09, status=1, ipAttribution=)]
    2022-04-04 ms2000001769569573

    收获很大!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1208543, encodeId=850212085434d, content=收获很大!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99956477261, createdName=ms2000001769569573, createdTime=Mon Apr 04 15:29:30 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200788, encodeId=26661200e8838, content=收获多多, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b415562646, createdName=ms9000001873897494, createdTime=Wed Mar 09 08:28:17 CST 2022, time=2022-03-09, status=1, ipAttribution=)]
    2022-03-09 ms9000001873897494

    收获多多

    0